Celsion Corporation Stock Nasdaq
Equities
US15117N4043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-20 | Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024 | CI |
05-13 | Transcript : Imunon, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 12.5M 17.11M |
---|---|---|---|---|---|
Net income 2024 * | -21M -28.74M | Net income 2025 * | -25M -34.21M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.64
x | P/E ratio 2025 * |
-0.81
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
Latest transcript on Celsion Corporation
Managers | Title | Age | Since |
---|---|---|---|
Stacy Lindborg
CEO | Chief Executive Officer | 53 | 21-06-03 |
Michael Tardugno
CHM | Chairman | 73 | 07-01-02 |
Sebastien Hazard
CTO | Chief Tech/Sci/R&D Officer | 53 | 12-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-06-07 | |
Frederick Fritz
BRD | Director/Board Member | 73 | 11-07-07 |
James Dentzer
BRD | Director/Board Member | 57 | 22-09-02 |
1st Jan change | Capi. | |
---|---|---|
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.50% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |